Relmada Therapeutics (RLMD): Orbimed Advisors LLC opened a new position $12.6M

2.61M

Shares reported

0.26%

Disclosed portfolio weight

$12.6M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

What came next

1. Mar 9, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
2. Mar 19, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. May 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. May 27, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Relmada Therapeutics

OQRO holds no insider, Congress, fund or contract record for Relmada Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RLMD page.

How this filing works

• SEC Form 13F

Other disclosures at Relmada Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Aug 28, 2025
• SEC Form 4Aug 28, 2025
• SEC Form 4Aug 28, 2025
• SEC Form 4May 20, 2025

Everything OQRO holds on this company is on its RLMD page.